Abstract
Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based compounds have been shown to inhibit activated p38 kinase in vitro and in vivo. We have developed a novel series of pyridinylimidazole-based compounds, which potently inhibit the p38 pathway by binding to unactivated p38 kinase and only weakly inhibiting activated p38 kinase activity in vitro.
MeSH terms
-
Animals
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Enzyme Inhibitors / toxicity
-
Esters / chemistry
-
Mice
-
Molecular Structure
-
Piperazine
-
Piperazines / chemistry
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
p38 Mitogen-Activated Protein Kinases / metabolism
Substances
-
Enzyme Inhibitors
-
Esters
-
Piperazines
-
Tumor Necrosis Factor-alpha
-
Piperazine
-
p38 Mitogen-Activated Protein Kinases